<DOC>
	<DOCNO>NCT00739466</DOCNO>
	<brief_summary>The main objective study assess safety efficacy Liposomal Alendronate treatment de novo stenotic lesion native coronary artery population undergo PCI implantation bare metal stent . Study hypothesis : Liposomal Alendronate reduce in-stent restenosis compare placebo .</brief_summary>
	<brief_title>Biorest Liposomal Alendronate With Stenting sTudy ( BLAST )</brief_title>
	<detailed_description>This Phase II dose-finding , randomize , multi-center , prospective , double blind clinical study . Subjects undergo percutaneous coronary intervention ( PCI ) Presillionâ„¢ CoCr bare metal stent randomize three group administer ( single dose intravenously ( IV ) peripheral venous catheter ) either : low dose Liposomal Alendronate 0.001 mg , high dose Liposomal Alendronate 0.01 mg , placebo ( IV saline infusion ) 1:1:1 basis . All subject undergo angiographic follow-up 6 month 110 subject enrol pre-specified site undergo intravascular ultrasound ( IVUS ) baseline follow-up 6 month .</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>1 . Subject eligible percutaneous coronary intervention . 2 . Subject acceptable candidate coronary artery bypass graft surgery . 3 . Subject stable angina pectoris 4 . Subject candidate elective stenting 2 lesion . General 1 . Any planned elective surgery percutaneous intervention within 6 month postprocedure . 2 . A previous coronary interventional procedure kind within 30 day prior procedure . 3 . Subject require staged procedure either target nontarget vessel within 9 month postprocedure . 4 . Any drug elute stent ( DES ) deployment within past 12 month . 5 . Any planned drug elute stent ( DES ) deployment procedure associate study within 3 month follow index procedure . 6 . Known hypersensitivity contraindication aspirin clopidogrel sensitivity contrast medium , adequately premedicated 7 . Concurrent medical condition life expectancy le 12 month . 8 . Documented leave ventricular ejection fraction ( LVEF ) &lt; 25 % recent evaluation . 9 . Evidence ST elevate myocardial infarction ( STEMI ) nonSTEMI troponin ( cTn ) level great equal 3 time normal limit time within 72 hour intend trial procedure . 10 . History cerebrovascular accident transient ischemic attack last 6 month . 11 . Leukopenia . 12 . Neutropenia 13 . Thrombocytopenia 14 . Serum creatinine level &gt; 2.5 mg/dl within 7 day prior index procedure . 15 . History bleed diathesis coagulopathy inability accept blood transfusion . 16 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , L605 Cobalt chromium alloy , Alendronate sensitivity contrast medium , adequately premedicated . 17 . History severe : Gastrointestinal disease , Immunodeficiency , Bone diseases Angiographic Exclusion Criteria 1 . Unprotected leave main coronary artery disease ( obstruction great 50 % leave main coronary artery protect least one nonobstructed bypass graft LAD Circumflex artery branch thereof ) . 2 . Any previous stent placement within 15 mm ( proximal distal ) target lesion ( ) . 3 . Target vessel exhibit lesion great 60 % diameter stenosis outside range 5 mm proximal distal target lesion ( ) base visual estimate online QCA . 4 . Target lesion ( ) exhibit intraluminal thrombus ( occupy &gt; 50 % true lumen diameter ) time . 5 . Lesion location aortoostial within 5 mm origin leave anterior descending ( LAD ) leave circumflex ( LCX ) . 6 . The target lesion ( ) require treatment device PTCA prior stent placement ( , limit , directional coronary atherectomy , excimer laser , rotational atherectomy , etc. ) . 7 . Target lesion ( ) side branch &gt; 2.0mm diameter . 8 . Target lesion ( ) involve bifurcation ( either stenosis main vessel major branch stenosis major branch ) . 9 . Target lesion ( ) severe calcification . 10 . Target vessel exhibit excessive tortuosity may impede stent delivery deployment target lesion ( ) . 11 . Target lesion ( ) locate native vessel distal anastomosis saphenous vein graft left/right internal mammary artery ( LIMA/RIMA ) bypass .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Liposomal Alendronate</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Coronary stenting</keyword>
	<keyword>de novo stenotic lesion</keyword>
	<keyword>Native coronary artery</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Bare metal stent</keyword>
	<keyword>Presillion CoCr coronary stent</keyword>
</DOC>